USFDA concludes GMP inspection at Piramal Pharma’s Telangana facility

16 Feb 2026 Evaluate

United States Food and Drug Administration (USFDA) has concluded a general Good Manufacturing Practices (GMP) inspection at Piramal Pharma’s Digwal, Telangana, India facility. The inspection was conducted from February 09, 2026 to February 13, 2026.

At the conclusion of the inspection, the US FDA issued a Form-483, with 4 observations. These observations are related to enhancement in procedures and not related to data integrity and are indicated to be classified as a VAI (voluntary action indicated). The Company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.

The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.

Piramal Pharma Share Price

166.15 0.05 (0.03%)
19-Feb-2026 10:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1722.00
Dr. Reddys Lab 1285.10
Cipla 1351.60
Zydus Lifesciences 916.25
Lupin 2224.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×